AUL
OCUL icon

AlphaGrep UK Ltd’s Ocular Therapeutix OCUL Stock Holding History

AlphaGrep UK Ltd’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$279K Buy
+32,926
New +$314K 0.08% 548

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

AlphaGrep UK Ltd's OCUL Position: Q1 2026 in Review

AlphaGrep UK Ltd opened a new position in Ocular Therapeutix (OCUL) in Q1 2026: 32,926 shares worth $279K. The stake represents 0.08% of the portfolio and ranks #548 among its holdings.

270 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

  • AlphaGrep UK Ltd held 32,926 shares of Ocular Therapeutix worth $279K as of Q1 2026.
  • Ocular Therapeutix was a new AlphaGrep UK Ltd position in Q1 2026.
  • Ocular Therapeutix made up 0.08% of AlphaGrep UK Ltd's portfolio in Q1 2026, its #548 holding.
  • 270 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on AlphaGrep UK Ltd's 13F filing for Q1 2026, filed 13 Aug 2026.